Pentadecanoic Acid (C15:0): Food Sources and Health Effects

Pentadecanoic acid, also called C15:0, is a 15-carbon saturated fatty acid found mainly in dairy fat that has attracted serious scientific interest over the past several years. Unlike its even-chain cousins (the 16- and 18-carbon fats long blamed for raising heart disease risk), C15:0 has been linked in population studies to lower rates of type 2 diabetes, cardiovascular disease, and liver problems. Some researchers have gone further, arguing that it meets the criteria for a newly identified essential fatty acid, one that the body cannot make in adequate quantities and must get from food. That claim remains debated, but the accumulating cell, animal, and early human evidence paints a surprisingly favorable picture of a nutrient most people have never heard of.

Where Pentadecanoic Acid Comes From

C15:0 is an odd-chain saturated fatty acid, meaning its carbon backbone has 15 carbons rather than the more common 16 or 18. In whole milk, it makes up roughly 1% of total fatty acids, a tiny fraction compared to the even-chain saturated fats that account for about 68% of milk fat.¹ Despite that small share, dairy fat is the primary dietary source. Full-fat milk, butter, cream, and certain cheeses deliver the bulk of what most people consume. Some fish and ruminant meats contribute smaller amounts.

Blood levels of C15:0 track dietary intake closely enough that researchers use it as a biomarker for dairy fat consumption. In a multi-population European study, circulating C15:0 showed good ability to distinguish between low and high consumers of full-fat dairy products.² That tight diet-to-blood correlation is one reason some scientists believe C15:0 is primarily diet-dependent rather than something the body manufactures on its own.

This matters because dietary trends have been moving in the wrong direction for C15:0 intake. Decades of public health messaging to reduce saturated fat pushed consumers toward low-fat and skim dairy, and more recently toward plant-based alternatives that contain no C15:0 at all. Population-wide decreases in whole milk and butter consumption have corresponded with measurable declines in average circulating C15:0 levels.³ Whether that decline has health consequences is an open question, but the direction of the epidemiological evidence is not reassuring.

What Makes an Odd-Chain Fat Different

Most of the saturated fats in food have even numbers of carbons. C15:0’s odd-numbered chain gives it a quirky physical property that turns out to be biologically meaningful. When a 15-carbon fatty acid is embedded in a cell membrane alongside the usual 16- and 18-carbon fats, its terminal methyl group ends up slightly out of phase with the neighboring chains. This misalignment prevents the two halves of the membrane from packing together as tightly as they otherwise would, resulting in looser lateral packing and greater membrane fluidity.⁴

The practical effect resembles what happens when you add an unsaturated fat with a kink in its chain, but without the vulnerability to oxidation that comes with double bonds. In other words, C15:0 can make membranes more flexible and functional while remaining chemically stable. This matters for every cell in the body, but it seems especially relevant for red blood cells, which need pliable membranes to squeeze through tiny capillaries.

Mitochondria and Energy Production

Beyond membrane effects, C15:0 appears to help mitochondria run more efficiently. Research has shown that pure C15:0 rescues mitochondrial function at complex II of the electron transport chain by increasing production of succinate, a key molecule that feeds into this step of energy generation. In supplemented cells, mitochondrial superoxide levels dropped by roughly 20% to 30% compared to unsupplemented controls, suggesting that electrons were flowing through the chain more cleanly with fewer leaking out to form damaging reactive oxygen species.⁵

Reactive oxygen species are a normal byproduct of energy production, but when too many accumulate they damage DNA, proteins, and membranes. This is one of the core mechanisms behind aging and chronic disease. The fact that C15:0 can dial down that leakage at the mitochondrial level helps explain why higher blood levels of this fat keep showing up alongside better health outcomes in epidemiological studies.

Signaling Pathways and Receptor Activity

C15:0 does not just sit passively in membranes. It actively interacts with several important cellular signaling systems. It functions as a dual partial agonist of PPAR-alpha and PPAR-delta receptors, which regulate lipid metabolism and inflammation. It activates AMPK, a master metabolic sensor that promotes energy balance, and suppresses mTOR, a growth-signaling pathway whose overactivity is implicated in aging and cancer.⁶ It also selectively inhibits HDAC6, a histone deacetylase involved in inflammation and protein quality control.⁷

Tested across a broad human cell platform that includes endothelial cells, fibroblasts, macrophages, and T-cells, C15:0 at a concentration of 17 micromolar produced statistically significant changes in 36 different biomarkers.⁸ That breadth of activity across so many cell types is unusual for a single fatty acid and suggests that the downstream health effects seen in population studies are not just statistical noise from confounded dairy consumption.

Associations with Diabetes and Heart Disease

The epidemiological evidence connecting C15:0 to metabolic health is strikingly consistent. In the Insulin Resistance Atherosclerosis Study, a prospective cohort that followed participants over time, higher serum C15:0 was associated with a 27% lower risk of developing type 2 diabetes after adjusting for demographics, lifestyle, and diet.⁹ That’s a meaningful reduction, and it held up even after accounting for factors like overall fat intake and physical activity.

The cardiovascular picture follows a similar pattern. While even-chain saturated fats like palmitic acid (C16:0) have been linked to increased inflammation and heart disease risk, higher circulating levels of odd-chain fats like C15:0 have been associated with lower risks of cardiovascular disease, metabolic syndrome, and chronic inflammation.¹⁰ This creates an awkward situation for dietary guidelines that lump all saturated fats together. The even-chain saturated fats that dominate dairy (making up roughly 68% of milk fat) may indeed pose risks, but the tiny fraction of odd-chain fats appears to move in the opposite direction.

Liver Protection

Nonalcoholic fatty liver disease is one of the fastest-growing health problems worldwide, driven largely by diets high in sugar and refined carbohydrates. C15:0 has shown promise in animal models of this condition. In mice fed a high-fat diet to induce fatty liver disease, treatment with pentadecanoic acid substantially reduced lipid droplet accumulation in liver tissue, as confirmed by histological staining.¹¹ C15:0 also reduced levels of alanine transaminase, a liver enzyme that rises when liver cells are damaged, along with pro-inflammatory cytokines associated with the progression from simple fatty liver to the more dangerous inflammatory stage of the disease.¹²

This is still animal data, and the jump from mice to humans is always uncertain. But given that no approved drug specifically targets early-stage fatty liver disease, a dietary fatty acid that can attenuate the condition in controlled models is worth watching.

Anti-Inflammatory Effects

Chronic low-grade inflammation drives much of the damage in diabetes, heart disease, and liver disease, so the anti-inflammatory activity of C15:0 ties many of these findings together. In human cell-based disease systems, C15:0 lowered levels of multiple inflammatory markers including MCP-1, IL-6, IL-8, and VCAM-1.¹³ Most of the effects were anti-inflammatory, and the breadth of markers affected suggests the mechanism is not limited to a single pathway.

Animal studies of inflammatory bowel disease have added more detail. In a mouse model of colitis, C15:0 supplementation altered the expression of 20 genes involved in immune and inflammatory pathways, including several interleukins and matrix metalloproteinases involved in tissue remodeling and immune cell recruitment.¹⁴ This is early-stage research, but it suggests that C15:0’s anti-inflammatory reach extends beyond metabolic tissues to the gut.

Red Blood Cell Stability and the Dolphin Connection

One of the more unexpected chapters in the C15:0 story involves bottlenose dolphins. Researchers studying chronic anemia in managed dolphin populations noticed that animals fed diets lower in odd-chain fatty acids had more fragile red blood cells. When the dolphins’ diets were modified to increase C15:0 intake from about 1.3 grams per day to 4.5 grams per day, erythrocyte C15:0 concentrations rose sharply and hemoglobin levels improved.¹⁵ The anemia was attenuated within one to three months, with both reticulocyte counts (a marker of the body scrambling to make new red blood cells) and red blood cell distribution width declining toward healthy ranges.¹⁶

This dolphin work was actually the starting point for much of the subsequent human-focused research on C15:0. In laboratory models, daily oral C15:0 supplementation raised hemoglobin, raised hematocrit, raised red blood cell count, and lowered the markers of red blood cell fragility and compensatory production, all consistent with membranes becoming sturdier and red blood cells surviving longer in circulation.¹⁷ The membrane-fluidity mechanism described earlier likely explains why: red blood cells with more C15:0 incorporated into their membranes are more flexible and less prone to rupture.

An interesting finding from the dolphin data was that increasing age correlated with declining serum C15:0, a pattern also seen in humans and one that may partially explain why red blood cell fragility and anemia become more common with age.¹⁸

Supplementation in Humans

Most of the mechanistic evidence for C15:0 comes from cell studies and animal models. The human clinical data is still thin, but a randomized controlled trial in young adults with overweight and obesity tested oral C15:0 supplementation over 12 weeks. Supplementation produced a significant increase in plasma C15:0 levels, with a mean adjusted increase of about 2 micrograms per milliliter above the placebo group.¹⁹ The supplement was well tolerated, though larger and longer trials are needed to determine whether the metabolic benefits seen in observational studies and animal work translate into measurable disease prevention in humans.

On the pharmacokinetic side, C15:0 appears to be absorbed by a mechanism that is somewhat resistant to lipase inhibition. In a study where healthy subjects took the fat-blocking drug orlistat alongside oral fatty acids, absorption of the 17-carbon odd-chain fat (heptadecanoic acid) dropped dramatically, but C15:0 absorption was unchanged.²⁰ This suggests C15:0 may use a different absorption route than typical dietary fats, though the implications for supplementation strategies are still being worked out.

Safety Profile

For a saturated fatty acid, C15:0 has a reassuringly clean safety record in the testing done so far. In a 14-day oral dosing study, rats received C15:0 at doses up to 350 milligrams per kilogram of body weight daily. No deaths occurred, no abnormal behaviors were observed, and body weights, organ-to-body-weight ratios, clinical chemistry values, and tissue histology of the liver, kidney, heart, and adrenal glands were all comparable to untreated controls.²¹ The 350 mg/kg dose in a rat is a high dose by human standards; scaled down, it would far exceed what anyone would get from food or a reasonable supplement.

The human trial data, while limited to 12 weeks, showed no concerning safety signals either. Still, the long-term safety of supplementing a saturated fatty acid at pharmacological doses is something that deserves more study. The argument from C15:0 proponents is that this is a naturally occurring nutrient being restored to historically normal levels rather than a drug being introduced at unnatural concentrations, but that framing only holds if the supplemented amounts stay within the range that food-based diets used to provide.

The Essential Fatty Acid Debate

The most provocative claim about C15:0 is that it deserves to be classified as the third essential fatty acid, joining the long-established alpha-linolenic acid (an omega-3) and linoleic acid (an omega-6). To earn that status, a fatty acid needs to meet three criteria: it must be required for healthy function, the body must not make enough of it on its own, and dietary intake must be necessary to maintain adequate levels. Researchers have argued that C15:0 checks all three boxes. Circulating levels closely mirror dietary intake, suggesting limited endogenous production, and lower blood levels are consistently associated with worse metabolic outcomes.²²

Not everyone agrees. One review noted that the body does produce some C15:0 through alpha-oxidation in peroxisomes and through de novo lipogenesis, and gut bacteria also contribute.²³ The question is whether those endogenous sources are sufficient. A mini-review concluded that C15:0 is not synthesized in sufficient quantities on its own and must be provided by the diet.²⁴ But calling something “essential” is a formal designation that requires consensus from nutrition authorities, and that consensus has not materialized. The evidence is suggestive but still mostly associational in humans, and the formal scientific bodies that set dietary guidelines have not weighed in.

What makes the debate more than academic is the practical implication. If C15:0 truly is essential, then the multi-decade push to reduce dairy fat consumption may have inadvertently created a widespread nutritional deficiency. That is a big claim, and the field needs larger and longer human trials before it can be made confidently. But the mechanistic story is coherent: C15:0 stabilizes cell membranes, improves mitochondrial efficiency, activates metabolic sensors, and damps inflammation through multiple pathways. Whether it earns the word “essential” or simply turns out to be a beneficial nutrient that many people get too little of, the practical takeaway may end up being the same.

Microalgae and Future Sourcing

One practical challenge with C15:0 is that relying on dairy fat as the sole source creates tension with environmental and ethical concerns around animal agriculture. Researchers have begun exploring alternative sources, and certain species of microalgae appear promising. The diatom Melosira nummuloides produces pentadecanoic acid as a major fatty acid component, and extracts from this microalga demonstrated hepatoprotective effects in the same mouse models of fatty liver disease where C15:0 showed benefit.²⁵ If scalable microalgal production proves feasible, it could provide a vegan-compatible and environmentally lighter source of C15:0 that sidesteps the dairy question entirely. A pure synthetic form of C15:0, marketed as a supplement, already exists and was the version used in the human clinical trial. But sourcing it from living organisms that naturally concentrate the molecule could bring costs down and appeal to consumers who prefer whole-food-derived nutrients.